Vascular Biogenics Ltd (VBLT)

[gr8db8]

The bold part is key, imo. If there was no difference found in the 2 cohorts except for what was reported, then that is pretty significant. Phase 3 interim is a few weeks away so we'll see.

Whereas brief exposure to VB-111 was associated with tumor progression in most patients, longer exposure to VB-111 (median= 4, mean=4.7 doses) led to attenuation of tumor growth kinetics (median % increase (MPI) per 30 days: 0.6 vs 14.1, p=0.0032). Furthermore, tumor regression was more frequent upon longer exposure to VB-111; only 16% of patients with limited exposure to VB-111 had tumors shrink below baseline dimensions during the first 100 days, compared to 61% of patients who continued to receive VB-111 through progression (p=0.002; McNemar’s test). Except for longer treatment with VB-111 leading to favorable OS, there was no evidence for difference between the two cohorts in any of the criteria tested, including patient characteristics, initial tumor growth kinetics, and Avastin treatment of both groups.

http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2278715